Publication | Open Access
SUMO pathway inhibition targets an aggressive pancreatic cancer subtype
99
Citations
47
References
2020
Year
SUMO inhibitor-based therapies should be further developed for an aggressive PDAC subtype.
| Year | Citations | |
|---|---|---|
Page 1
Page 1